Loading...
Printed on 4/19/2026
For informational purposes only. This is not medical advice.
APRI is a non-invasive fibrosis marker that combines AST elevation relative to lab ULN and thrombocytopenia signal from platelet count. It is commonly used in chronic hepatitis and broader fibrosis triage pathways.
Formula: APRI = ((AST / AST ULN) x 100) / Platelets
Higher APRI values generally indicate greater fibrosis likelihood, while lower values suggest lower probability of advanced fibrosis.
Use APRI for non-invasive fibrosis risk stratification when AST and platelets are available, especially in initial hepatology triage.
APRI can be distorted by acute hepatitis flares, lab-specific AST ULN definitions, and non-hepatic causes of thrombocytopenia.
For related assessments, see FIB-4, AST/ALT Ratio and MELD Score.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
Estimate liver fibrosis risk using age, AST, ALT, and platelet count with the FIB-4 index.
GastroenterologyCalculate the AST/ALT ratio as an adjunct liver injury pattern marker in hepatology evaluation.
ClinicalCalculate the MELD and MELD-Na scores to assess liver disease severity and transplant priority. Uses bilirubin, INR, creatinine, and sodium.
ClinicalCalculate the Child-Pugh score to classify the severity of chronic liver disease and estimate prognosis. Uses bilirubin, albumin, INR, ascites, and encephalopathy.